N

Nichi-Iko Pharmaceutical Co Ltd
TSE:4541

Watchlist Manager
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Watchlist
Price: 0.0001 JPY Market Closed
Market Cap: 776 550.9T JPY
Have any thoughts about
Nichi-Iko Pharmaceutical Co Ltd?
Write Note
Nichi-Iko Pharmaceutical Co Ltd
/
Cash Flow Statement
/
Cash Paid for Dividends

Nichi-Iko Pharmaceutical Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nichi-Iko Pharmaceutical Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Cash Paid for Dividends
-¥644m
CAGR 3-Years
28%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash Paid for Dividends
-¥294.7B
CAGR 3-Years
-1%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
Daiichi Sankyo Co Ltd
TSE:4568
Cash Paid for Dividends
-¥95.8B
CAGR 3-Years
-22%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Cash Paid for Dividends
-¥66.8B
CAGR 3-Years
-6%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash Paid for Dividends
-¥131.6B
CAGR 3-Years
-10%
CAGR 5-Years
-18%
CAGR 10-Years
-18%
Astellas Pharma Inc
TSE:4503
Cash Paid for Dividends
-¥125.5B
CAGR 3-Years
-17%
CAGR 5-Years
-12%
CAGR 10-Years
-8%
No Stocks Found

Nichi-Iko Pharmaceutical Co Ltd
Glance View

Market Cap
776 550.9T JPY
Industry
Pharmaceuticals

Nichi-Iko Pharmaceutical Co., Ltd., founded in Toyama, Japan, weaves its narrative around the essential fabric of healthcare by pioneering affordable and accessible medication. As a distinguished player in the generic pharmaceutical industry, Nichi-Iko specializes in the development, manufacture, and sale of a broad spectrum of generic drugs. Driven by the mission to enhance quality of life, the company meticulously focuses on producing high-quality, cost-effective alternatives to branded medications, thereby easing the financial burden on healthcare systems and patients alike. Its portfolio spans various therapeutic areas, strengthening its presence in both domestic and international markets. By investing strategically in R&D and leveraging advanced production techniques, Nichi-Iko ensures that its offerings meet rigorous standards, reinforcing trust and reliability in its brand. Financially, Nichi-Iko's revenue stream primarily hinges on the consistent demand for generics, amplified by the growing global emphasis on reducing healthcare costs. Licensing agreements and partnerships further bolster its financial framework, allowing the company to expand its product range and reach. The business model thrives on optimizing supply chain efficiencies and achieving economies of scale, translating into competitive pricing. Nichi-Iko’s commitment to innovation is not confined to generics; it is also venturing into biosimilars, tapping into a burgeoning market with expansive growth potential. By aligning its strategic direction with emerging healthcare trends and regulatory landscapes, Nichi-Iko positions itself as a resilient entity capable of sustaining its growth trajectory in a dynamic pharmaceutical sector.

Intrinsic Value
Not Available
N
What is Intrinsic Value?

See Also

What is Nichi-Iko Pharmaceutical Co Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-644m JPY

Based on the financial report for Mar 31, 2022, Nichi-Iko Pharmaceutical Co Ltd's Cash Paid for Dividends amounts to -644m JPY.

What is Nichi-Iko Pharmaceutical Co Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 5Y
19%

Over the last year, the Cash Paid for Dividends growth was 66%. The average annual Cash Paid for Dividends growth rates for Nichi-Iko Pharmaceutical Co Ltd have been 28% over the past three years , 19% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.